Question 1

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

Question 2

How does palbociclib compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from palbociclib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and tests during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific risks associated with this trial that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition changes during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer clinical trial (NCT03969121). Contact the study team or your healthcare provider for specific answers.

What this study is about